Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 21, 2021 - Issue 3: Pharmacoeconomics in Oncology: Direct and Indirect Costs
Submit an article Journal homepage
3,888
Views
8
CrossRef citations to date
0
Altmetric
Original research

Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing

Clémence T. B. Pasmansa Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The NetherlandsView further author information
,
Bastiaan B. J. Topsb Princess Máxima Center for Pediatric Oncology, Bilthoven, The NetherlandsView further author information
,
Elisabeth M. P. Steeghsc Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The NetherlandsView further author information
,
Veerle M. H. Coupéd Department of Epidemiology and Biostatistics, Amsterdam University Medical Center, VU Amsterdam, Amsterdam, The NetherlandsView further author information
,
Katrien Grünbergc Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The NetherlandsView further author information
,
Eiko K de Jongc Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The NetherlandsView further author information
,
Ed M. D. Schuuringe Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The NetherlandsORCID Iconhttps://orcid.org/0000-0003-3655-143XView further author information
ORCID Icon,
Stefan M. Willemsf Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands;g PALGA Foundation, Houten, The NetherlandsView further author information
,
Marjolijn J. l. Ligtenbergc Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands;h Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The NetherlandsView further author information
,
Valesca P. Retèli Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands;j Department of Health Technology and Services Research, University of Twente, Enschede, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-5624-3234View further author information
ORCID Icon,
Hans van Snellenbergk Hartwig Medical Foundation, Amsterdam, The NetherlandsView further author information
,
Ewart de Bruijnk Hartwig Medical Foundation, Amsterdam, The NetherlandsView further author information
,
Edwin Cuppenk Hartwig Medical Foundation, Amsterdam, The Netherlands;l Center for Molecular Medicine and Cancer Genomics Netherlands, University Medical Center Utrecht, Utrecht University, Utrecht, The NetherlandsView further author information
&
Geert W. J. Frederixa Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The NetherlandsCorrespondence[email protected]
View further author information
 show all
Pages 413-414 | Received 03 Feb 2021, Accepted 12 Apr 2021, Published online: 06 May 2021

References

  • Diamandis M, White NM, Yousef GM. Personalized medicine: marking a new epoch in cancer patient management. Mol Cancer Res. 2010;8(9):1175–1187.
  • Jackson SE, Chester JD. Personalised cancer medicine. Int J Cancer. 2015;137(2):262–266.
  • Abdul-Karim RM, Cowey CL. Challenging the standard of care in advanced melanoma: focus on pembrolizumab. Cancer Manag Res. 2017;9:433–442.
  • Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
  • Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
  • Zorginstituut Nederland. Medicijnkosten.nl, 2/19 update. [cited 2020 Nov 4]. Available from: https://www.medicijnkosten.nl/
  • Bannon AE, Klug LR, Corless CL, et al. Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors. Expert Rev Mol Diagn. 2017;17(5):445–457.
  • Cheng L, Lopez-Beltran A, Massari F, et al. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018;31(1):24–38.
  • Kruglyak KM, Lin E, Ong FS. Next-generation sequencing and applications to the diagnosis and treatment of lung cancer. Adv Exp Med Biol. 2016;890:123–136.
  • Sinicrope FA, Okamoto K, Kasi PM, et al. Molecular biomarkers in the personalized treatment of colorectal cancer. Clin Gastroenterol Hepatol. 2016;14(5):651–658.
  • Sholl L. Molecular diagnostics of lung cancer in the clinic. Transl Lung Cancer Res. 2017;6(5):560–569.
  • van Amerongen RA, Retèl VP, Coupé VM, et al. Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis. Ecancermedicalscience. 2016;10:684.
  • Brittain HK, Scott R, Thomas E. The rise of the genome and personalised medicine. Clin Med (Lond). 2017;17(6):545–551.
  • Nakagawa H, Fujita M. Whole genome sequencing analysis for cancer genomics and precision medicine. Cancer Sci. 2018;109(3):513–522.
  • Sabatini LM, Mathews C, Ptak D, et al. Genomic sequencing procedure microcosting analysis and health economic cost-impact analysis: a report of the association for molecular pathology. J Mol Diagn. 2016;18(3):319–328.
  • Marino P, Touzani R, Perrier L, et al. Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study. Eur J Hum Genet. 2018;26(3):314–323.
  • van Nimwegen KJ, van Soest RA, Veltman JA, et al. Is the $1000 genome as near as we think? A cost analysis of next-generation sequencing. Clin Chem. 2016;62(11): 1458–1464.
  • Plöthner M, Frank M, Graf von der Schulenburg JM Cost analysis of whole genome sequencing in German clinical practice. Eur J Health Econ. 2017;18(5):623–633.
  • Wetterstrand KA. DNA sequencing costs: data from the NHGRI genome sequencing program (GSP), 2/19 update. [cited 2020 nov 4]. Available from: www.genome.gov/sequencingcosts
  • Schwarze K, Buchanan J, Fermont JM, et al. The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom. Genet Med. 2019;2;1–10.
  • U.S. Food and Drug Administration. Drugs, [cited 2020 nov 4]. Available from: https://www.fda.gov/drugs
  • Casparie M, Tiebosch AT, Burger G, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007;29:19–24.
  • Lievens Y, Van den Bogaert W, Kesteloot K. Activity-based costing: a practical model for cost calculation in radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57(2):522–535.
  • Smits AJ, Kummer JA, Hinrichs JW, et al. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol. 2012;35(3):189–196.
  • Kerner GS, Schuuring E, Sietsma J, et al. Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome. PLoS One. 2013;8(7):e70346.
  • Cho M, Ahn S, Hong M, et al. Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center’s experiences. Oncotarget. 2017;8(26):42478–42486.
  • Morris S, Subramanian J, Gel E, et al. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS ONE. 2018;13(4):e0196556.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.